ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

Ultragenyx Reports Third Quarter 2021 Financial Results and Corporate Update

02 Nov 2021 16:05:03 By Nasdaq GlobeNewswire

Ultragenyx to Host Conference Call for Third Quarter 2021 Financial Results and Corporate Update

26 Oct 2021 16:05:00 By Nasdaq GlobeNewswire

Ultragenyx to Present at Jefferies Gene Therapy/Editing Summit

25 Oct 2021 16:05:00 By Nasdaq GlobeNewswire

Ultragenyx Initiates Cyprus2+, a Pivotal Clinical Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

18 Oct 2021 08:00:01 By Nasdaq GlobeNewswire

GeneTx and Ultragenyx Announce First Patient Dosed in Canada in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome

07 Oct 2021 08:00:01 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

04 Oct 2021 16:05:00 By Nasdaq GlobeNewswire

Ultragenyx Announces Crysvita® (burosumab) and UX143 (setrusumab) Data Presentations at Upcoming American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting

27 Sep 2021 16:30:00 By Nasdaq GlobeNewswire

GeneTx and Ultragenyx Announce FDA has Removed Clinical Hold on Phase 1/2 Clinical Study of GTX-102 for the Treatment of Angelman Syndrome in the U.S.

27 Sep 2021 08:00:01 By Nasdaq GlobeNewswire

Ultragenyx to Present at Morgan Stanley Healthcare Conference

07 Sep 2021 16:30:00 By Nasdaq GlobeNewswire

MEDIA ADVISORY: Ultragenyx Canada Announces Health Canada Approval of a Second Indication for Crysvita™ (Burosumab Injection) for the Treatment of Tumour Induced Osteomalacia in Adults

07 Sep 2021 08:00:03 By Nasdaq GlobeNewswire